|
|
|
|
Amgen Sees Positive Data in Bone Drug Study
THOUSAND OAKS, Calif.(AP) ' Amgen Inc. said its osteoporosis drug candidate denosumab beat a rival drug in reducing and delaying the rate of fractures in men with prostate cancer during a study. The drug, also called Prolia, is viewed by Wall Street as...
|
|
|
Biogen Idec Reports Full Year and Fourth Quarter 2009 Results
Biogen Idec Inc., a global biotechnology company involved in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.Full Year 2009 Highlights: Total revenues in...
|
|
|
Glaxo Considering Job Cuts at UK Research Center
LONDON (AP) ' GlaxoSmithKline PLC said Tuesday that it has begun consultations with workers on cutting jobs at a British research facility, an early step in its plans announced a week ago to shift its research focus.Glaxo said the consultation involved...
|
|
|
Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc
Sanofi-aventis announced today that it has successfully completed its tender offer for all outstanding shares of common stock of Chattem, Inc.The tender offer and withdrawal rights expired at 12:00 midnight, New York City time, on February 8, 2010. The...
|
|
|
YM BioSciences Merges with Cytopia Ltd.; Reports Second Quarter Loss of $3.4M
Toronto-area biopharmaceutical company YM BioSciences Inc.announced Monday it has merged with Cytopia Ltd., a clinical-stage drug development company based in Melbourne, Australia. YM said the merger with privately held Cytopia was completed in late...
|
|
|
Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the FDA on a Special Protocol Assessment (SPA) for the Phase 3...
|
|
|
FDA Issues Complete Response Letter Regarding Strativa Pharmaceutical's NDA for Zuplenz Oral Soluble Film
Strativa Pharmaceuticals has announced that the FDA issued a complete response letter regarding the new drug application (NDA) for Zuplenz (ondansetron) oral soluble film for the prevention of nausea and vomiting associated with highly- and moderately...
|
|
|
Multiple Sclerosis Experts Join Biogen Idec's Research and Development Team
Biogen Idec, a global biotechnology company involved in the discovery, development, manufacturing and commercialization of innovative therapies, today announced that John R.Richert, M.D., will be joining the Company as a Senior Fellow in Neurology Research...
|
|
|
Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
Novavax, Inc.announced today that the company has decided to discontinue negotiations in its pursuit of the previously announced collaboration with ROVI Pharmaceuticals (Madrid: ROVI) to develop Novavax's virus-like-particle (VLP)-based vaccines against...
|
|
|
Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP
agent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has received FDA approval of labetalol hydrochloride (HCl) injection, USP, commonly used to control severe hypertension.The product will be available in...
|
